CLINICAL QUESTION
Does the human papillomavirus (HPV) vaccine protect against other malignancies in addition to cervical cancer?
BOTTOM LINE
In addition to a large reduction in oral, genital, and anal cancer, HPV vaccination in women impressively reduces the likelihood of developing many other cancers. The reduction is greater when the vaccine is administered between the ages of 9 and 14 years. Some HPV strains seem to trigger two proteins produced in the body that cause runaway cell growth. (Level of Evidence = 2b)
SYNOPSIS
The investigators identified nonpregnant women who had at least two visits documented in an electronic health record that was part of a global electronic health record network (TriNetX). They identified 347,934 women who had received an HPV vaccine and matched each one to a woman who did not receive the vaccination using eight categories. Women in both groups were followed up for up to 5 years. Overall, the vaccinated women had a lower risk of malignant neoplasms (hazard ratio = 0.38; 95% CI, 0.34–0.42). Mouth and oropharynx, digestive organ, respiratory, bone, soft tissue, breast, female genital organ, urinary tract, nervous system, thyroid, and other cancers were significantly less common in the vaccinated cohort. A greater reduction was observed in women vaccinated between the ages of 9 and 14 years compared with women vaccinated between the ages of 15 and 26 years, although both age groups had a reduction in risk.
Study Design: Cohort (retrospective)
Funding Source: Foundation
Setting: Population-based
Reference: Hung YM, Lin TT, Wang SI, et al. HPV vaccination is associated with lower risk of cancers among females. Am J Med. 2026;139(3):311-320.e12.
Read the full article
Get immediate access, anytime, anywhere.
Choose a single article, issue, or full-access subscription.
Earn up to 14 CME credits per issue.
